CN102078323A - 一种含米诺膦酸药物组合物 - Google Patents
一种含米诺膦酸药物组合物 Download PDFInfo
- Publication number
- CN102078323A CN102078323A CN2009102289015A CN200910228901A CN102078323A CN 102078323 A CN102078323 A CN 102078323A CN 2009102289015 A CN2009102289015 A CN 2009102289015A CN 200910228901 A CN200910228901 A CN 200910228901A CN 102078323 A CN102078323 A CN 102078323A
- Authority
- CN
- China
- Prior art keywords
- minodronic acid
- granulate
- pharmaceutical composition
- preparation
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229950011129 minodronic acid Drugs 0.000 title claims abstract description 28
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 239000008187 granular material Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 239000007779 soft material Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 238000004364 calculation method Methods 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract description 14
- 208000001132 Osteoporosis Diseases 0.000 abstract description 7
- 238000004090 dissolution Methods 0.000 abstract description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract description 7
- 239000003381 stabilizer Substances 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- -1 nitrogenous diphosphate compounds Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- GPAPAOGRNKUFGH-UHFFFAOYSA-N (1-hydroxy-2-imidazo[1,2-a]pyridin-3-yl-1-phosphonoethyl)phosphonic acid;hydrate Chemical compound O.C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 GPAPAOGRNKUFGH-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000008416 bone turnover Effects 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000037848 Metastatic bone disease Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000032183 Scleromalacia Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102289015A CN102078323A (zh) | 2009-12-01 | 2009-12-01 | 一种含米诺膦酸药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102289015A CN102078323A (zh) | 2009-12-01 | 2009-12-01 | 一种含米诺膦酸药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102078323A true CN102078323A (zh) | 2011-06-01 |
Family
ID=44084648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102289015A Pending CN102078323A (zh) | 2009-12-01 | 2009-12-01 | 一种含米诺膦酸药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102078323A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102204923A (zh) * | 2011-03-30 | 2011-10-05 | 北京美迪康信医药科技有限公司 | 一种治疗骨质疏松症的药物组合物 |
CN104771379A (zh) * | 2014-01-09 | 2015-07-15 | 山东新时代药业有限公司 | 一种米诺膦酸片剂及其制备方法 |
CN106619574A (zh) * | 2017-01-02 | 2017-05-10 | 佛山市腾瑞医药科技有限公司 | 一种微孔膜控释包衣米诺膦酸微丸及其制备方法 |
CN106667961A (zh) * | 2017-02-16 | 2017-05-17 | 佛山市腾瑞医药科技有限公司 | 一种米诺膦酸速释微丸制剂、制备方法 |
CN106667955A (zh) * | 2017-02-15 | 2017-05-17 | 佛山市腾瑞医药科技有限公司 | 一种米诺膦酸软胶囊制剂及其制备工艺 |
CN106821994A (zh) * | 2017-02-14 | 2017-06-13 | 佛山市腾瑞医药科技有限公司 | 一种米诺膦酸固体分散体制剂及其制备方法 |
CN106913546A (zh) * | 2015-12-28 | 2017-07-04 | 山东新时代药业有限公司 | 一种快速溶出的米诺膦酸片剂及其制备方法 |
-
2009
- 2009-12-01 CN CN2009102289015A patent/CN102078323A/zh active Pending
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102204923A (zh) * | 2011-03-30 | 2011-10-05 | 北京美迪康信医药科技有限公司 | 一种治疗骨质疏松症的药物组合物 |
CN102204923B (zh) * | 2011-03-30 | 2015-11-18 | 北京美迪康信医药科技有限公司 | 一种治疗骨质疏松症的药物组合物 |
CN104771379A (zh) * | 2014-01-09 | 2015-07-15 | 山东新时代药业有限公司 | 一种米诺膦酸片剂及其制备方法 |
CN104771379B (zh) * | 2014-01-09 | 2019-02-19 | 山东新时代药业有限公司 | 一种米诺膦酸片剂及其制备方法 |
CN106913546A (zh) * | 2015-12-28 | 2017-07-04 | 山东新时代药业有限公司 | 一种快速溶出的米诺膦酸片剂及其制备方法 |
CN106913546B (zh) * | 2015-12-28 | 2021-06-22 | 山东新时代药业有限公司 | 一种快速溶出的米诺膦酸片剂及其制备方法 |
CN106619574A (zh) * | 2017-01-02 | 2017-05-10 | 佛山市腾瑞医药科技有限公司 | 一种微孔膜控释包衣米诺膦酸微丸及其制备方法 |
CN106821994A (zh) * | 2017-02-14 | 2017-06-13 | 佛山市腾瑞医药科技有限公司 | 一种米诺膦酸固体分散体制剂及其制备方法 |
CN106667955A (zh) * | 2017-02-15 | 2017-05-17 | 佛山市腾瑞医药科技有限公司 | 一种米诺膦酸软胶囊制剂及其制备工艺 |
CN106667961A (zh) * | 2017-02-16 | 2017-05-17 | 佛山市腾瑞医药科技有限公司 | 一种米诺膦酸速释微丸制剂、制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078323A (zh) | 一种含米诺膦酸药物组合物 | |
CN101836974A (zh) | 一种含有重酒石酸卡巴拉汀的药物组合物及其制备方法 | |
CN105078915A (zh) | 一种利伐沙班片及其制备方法 | |
CN101485697B (zh) | 银杏酮酯分散片及其制备方法 | |
CN107753458A (zh) | 尼莫地平片剂药物组合物和制法 | |
CN104224831A (zh) | 一种叶酸类营养补充剂的制备方法 | |
CN104107173A (zh) | 一种罗氟司特片剂及其制备方法 | |
CN104434826B (zh) | 一种瑞舒伐他汀钙分散片 | |
CN106924237B (zh) | 一种含有恩格列净和盐酸二甲双胍的药物组合物 | |
CN110917161A (zh) | 一种甲硝唑片及其制备方法 | |
CN114767645B (zh) | 叶酸片及其制备方法 | |
CN106580898B (zh) | 一种灯盏花素分散片及制备方法 | |
CN102309462A (zh) | 一种阿托伐他汀钙片剂 | |
CN104606159A (zh) | 一种醋酸钙药物组合物及其制备方法 | |
CN106913544B (zh) | 一种快速溶出的吉非替尼片剂及其制备方法 | |
CN107929251A (zh) | 一种苯丁酸钠片及其制备方法 | |
CN101711753B (zh) | 兰索拉唑固体制剂的制备方法 | |
CN108440456A (zh) | 奥利司他与有机酸钙的共晶体及包含该共晶体的药物组合物 | |
CN106994121A (zh) | 一种用于治疗癌症的药物组合物 | |
CN108096207B (zh) | 一种罗他夫辛肠溶片的制备方法 | |
CN102488667A (zh) | 一种格列美脲片及其制备方法 | |
CN102198274B (zh) | 雷洛昔芬的环糊精包合物及其制剂的制备方法 | |
CN112535671A (zh) | 氨磺必利分散片的制备方法 | |
CN110354093A (zh) | 一种枸橼酸莫沙必利药物组合物 | |
CN104922083B (zh) | 磺胺嘧啶片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO., Free format text: FORMER OWNER: YAN JIE Effective date: 20120210 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120210 Address after: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Applicant after: Tianjin Hankang Pharmaceutical Biotechnology Co., Ltd. Address before: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Applicant before: Yan Jie |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110601 |